Insiders · SGMT

SGMT insider transactions

Sagimet Biosciences Inc. (SGMT) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

SGMT insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Sagimet Biosciences Inc., latest first. Follow anyone to get their next filing.

• George KembleExecutive Chairman, Director-$4.34M
• David HappelPresident & CEO, Director+$63.7K-$1.16M
• Elizabeth RozekChief Legal & Admin. Officer-$228K
• Beth C SeidenbergDirector
• Paul W. HoelscherDirector, since April 2024
• Jennifer JarrettDirector, since August 2024
• Elizabeth A GrammerDirector
• Anne M. PhillipsDirector, since August 2024
• Thierry ChaucheChief Financial Officer, since May 2024-$7,033
• Andreas GrauerChief Medical Officer, since April 2026
• Eduardo Bruno MartinsChief Medical Officer-$121K
• Timothy P WalbertDirector, since April 2024
• Merdad ParseyDirector

Recent Form 3, 4, and 5 filings for SGMT

• 90d
  Director Kemble George exercised 350,987 units of Series A Common Stock at a strike of $6.36 and sold $3,591,580 worth of Series A Common Stock (350,987 units at $10.23) as part of a pre-agreed trading plan (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 94d
  Director Kemble George exercised 20,206 units of Series A Common Stock at a strike of $6.36 and sold $201,147 worth of Series A Common Stock (20,206 units at $9.95) as part of a pre-agreed trading plan (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 116d
  President & CEO Happel David sold $497,068 worth of Series A Common Stock (64,051 units at $7.76), decreasing direct ownership by 8% to 741,570 units (SEC Form 4) (for tax liability)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 116d
  Chief Legal & Admin. Officer Rozek Elizabeth sold $81,832 worth of Series A Common Stock (10,545 units at $7.76), decreasing direct ownership by 4% to 224,414 units (SEC Form 4) (for tax liability)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 116d
  Director Kemble George sold $140,529 worth of Series A Common Stock (18,844 units at $7.46) as part of a pre-agreed trading plan, decreasing direct ownership by 23% to 62,161 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 153d
  SEC Form 4 filed by Director Seidenberg Beth C

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 153d
  SEC Form 4 filed by Director Hoelscher Paul W.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 153d
  SEC Form 4 filed by Director Jarrett Jennifer

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 153d
  SEC Form 4 filed by Director Grammer Elizabeth A

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 153d
  SEC Form 4 filed by Director Kemble George

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 153d
  SEC Form 4 filed by Director Phillips Anne M.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 166d
  SEC Form 4 filed by Chief Financial Officer Chauche Thierry

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 166d
  SEC Form 4 filed by Chief Medical Officer Grauer Andreas

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 166d
  SEC Form 4 filed by Chief Legal & Admin. Officer Rozek Elizabeth

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 166d
  SEC Form 4 filed by President & CEO Happel David

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 185d
  SEC Form 4 filed by Chief Medical Officer Grauer Andreas

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 185d
  SEC Form 3 filed by new insider Grauer Andreas

  3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 268d
  Chief Legal & Admin. Officer Rozek Elizabeth was granted 44,000 units of Series A Common Stock, increasing direct ownership by 23% to 234,959 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 268d
  Chief Medical Officer Martins Eduardo Bruno was granted 44,000 units of Series A Common Stock, increasing direct ownership by 43% to 147,296 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 268d
  President & CEO Happel David was granted 128,000 units of Series A Common Stock, increasing direct ownership by 19% to 805,621 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 268d
  Chief Financial Officer Chauche Thierry was granted 44,000 units of Series A Common Stock, increasing direct ownership by 280% to 59,688 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 276d
  President & CEO Happel David sold $64,865 worth of Series A Common Stock (12,101 units at $5.36), decreasing direct ownership by 2% to 677,621 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 276d
  Chief Financial Officer Chauche Thierry sold $7,033 worth of Series A Common Stock (1,312 units at $5.36), decreasing direct ownership by 8% to 15,688 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 276d
  Chief Medical Officer Martins Eduardo Bruno sold $19,511 worth of Series A Common Stock (3,640 units at $5.36), decreasing direct ownership by 3% to 103,296 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 276d
  Chief Legal & Admin. Officer Rozek Elizabeth sold $14,054 worth of Series A Common Stock (2,622 units at $5.36), decreasing direct ownership by 1% to 190,959 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 359d
  Executive Chairman Kemble George sold $289,979 worth of Series A Common Stock (37,688 units at $7.69), decreasing direct ownership by 32% to 81,005 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 374d
  Chief Legal & Admin. Officer Rozek Elizabeth was granted 9,855 units of Series A Common Stock, increasing direct ownership by 5% to 193,581 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 480d
  President & CEO Happel David sold $598,115 worth of Series A Common Stock (65,478 units at $9.13), decreasing direct ownership by 9% to 689,722 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 480d
  Chief Medical Officer Martins Eduardo Bruno sold $75,607 worth of Series A Common Stock (8,277 units at $9.13), decreasing direct ownership by 7% to 106,936 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 480d
  General Counsel and CCO Rozek Elizabeth sold $98,471 worth of Series A Common Stock (10,780 units at $9.13), decreasing direct ownership by 6% to 183,726 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 523d
  SEC Form 4 filed by Director Walbert Timothy P

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 523d
  SEC Form 4 filed by Director Seidenberg Beth C

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 523d
  SEC Form 4 filed by Director Phillips Anne M.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 523d
  SEC Form 4 filed by Director Kemble George

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 523d
  SEC Form 4 filed by Director Jarrett Jennifer

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 523d
  SEC Form 4 filed by Director Hoelscher Paul W.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 523d
  SEC Form 4 filed by Director Grammer Elizabeth A

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 646d
  Chief Medical Officer Martins Eduardo Bruno was granted 34,000 units of Series A Common Stock, increasing direct ownership by 42% to 115,213 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 646d
  President & CEO Happel David was granted 116,000 units of Series A Common Stock, increasing direct ownership by 18% to 755,200 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 646d
  General Counsel and CCO Rozek Elizabeth was granted 34,000 units of Series A Common Stock, increasing direct ownership by 21% to 194,506 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 646d
  Chief Financial Officer Chauche Thierry was granted 17,000 units of Series A Common Stock (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 832d
  SEC Form 4 filed by Director Jarrett Jennifer

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 832d
  SEC Form 4 filed by Director Phillips Anne M.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 832d
  SEC Form 3 filed by new insider Jarrett Jennifer

  3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 832d
  SEC Form 3 filed by new insider Phillips Anne M.

  3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 843d
  Executive Chairman Kemble George sold $74,830 worth of Series A Common Stock (23,625 units at $3.17), decreasing direct ownership by 17% to 118,693 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 845d
  Chief Medical Officer Martins Eduardo Bruno sold $25,910 worth of Series A Common Stock (8,357 units at $3.10), decreasing direct ownership by 9% to 81,213 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 845d
  General Counsel and CCO Rozek Elizabeth sold $33,830 worth of Series A Common Stock (10,914 units at $3.10), decreasing direct ownership by 6% to 160,506 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 845d
  Executive Chairman Kemble George sold $43,605 worth of Series A Common Stock (14,062 units at $3.10), decreasing direct ownership by 9% to 142,318 units (SEC Form 4)

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 891d
  SEC Form 4 filed by Walbert Timothy P

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 891d
  SEC Form 4 filed by Seidenberg Beth C

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 891d
  SEC Form 4 filed by Parsey Merdad

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 891d
  SEC Form 4 filed by Hoelscher Paul W.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 891d
  SEC Form 4 filed by Grammer Elizabeth A

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 921d
  SEC Form 4 filed by Chauche Thierry

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 921d
  SEC Form 3 filed by new insider Chauche Thierry

  3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 955d
  SEC Form 4 filed by Walbert Timothy P

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 955d
  SEC Form 4 filed by Hoelscher Paul W.

  4 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 955d
  New insider Walbert Timothy P claimed ownership of 2,200 units of Series A Common Stock (SEC Form 3)

  3 - Sagimet Biosciences Inc. (0001400118) (Issuer)
• 955d
  SEC Form 3 filed by new insider Hoelscher Paul W.

  3 - Sagimet Biosciences Inc. (0001400118) (Issuer)